Pharmaceutical Network December 8th my country Pharmaceutical Research and Development Outsourcing Service is accelerating。Yesterday，The Medicine Chemical Research Award approved by the Ministry of Science and Technology announced this year's winning list in Diaoyutai National Hotel，From Capital Medical University、The School of Life Sciences of Tsinghua University、18 scientific researchers from the Third Hospital of Peking University won awards。At the same time, the development of my country's current pharmaceutical research and development outsourcing services is combed，and predict that my country's pharmaceutical research and development outsourcing services may exceed 40 billion yuan within three years。According to an introduction，Last year, my country's CRO (pharmaceutical research stake sports betting appand stake sports betting appdevelopment outsourcing) market size was about 17.9 billion yuan，accounts for about 9.2%of the global CRO total scale。Domestic CRO companies are mainly distributed in Beijing、Shanghai、Nanjing、Guangzhou、Wuxi、Chengdu，The leading domestic CRO companies are Yao Ming Kangde、​​Shanghua Medicine、Tiger Medicine。

 

Current，my country's CRO is also facing many challenges while developing rapidly，If the approval time is long，New drug research and development、New medicine design、Pre -clinical research and other projects with high technological innovation content are relatively low，The construction of the drug clinical trial institution needs to be strengthened.。

 

But the domestic CRO market also has a certain congenital advantage at the same time，Including a huge domestic market、Stake Sports BettingHuman stake sports betting appresources cost advantage and rich case resources，These conditions all promote the high growth of the domestic CRO market。With the rise of the domestic new drug research and development boom，It is expected that my country's pharmaceutical research and development outsourcing service industry will maintain a growth of 22%to 25%in the next 3 to 5 years.，It is expected to exceed 40 billion yuan in 2017。